Estrogen Replacement Therapy in a Man with Congenital Aromatase Deficiency: Effects of Different Doses of Transdermal Estradiol on Bone Mineral Density and Hormonal Parameters
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The effects of different doses of transdermal estradiol (TE) on bone mineral density (BMD) in a man with aromatase deficiency were evaluated. The study protocol was divided in the following four phases: phase 1, before estradiol treatment; phase 2, 50 microg TE twice weekly for 6 months; phase 3, 25 microg TE twice weekly for 9 months; and phase 4, 12.5 microg TE twice weekly for 9 months. X-rays of hands, legs, and pelvis were performed, and BMD of the lumbar spine, hormonal parameters (LH, FSH, testosterone, and estradiol), and markers of bone turnover were determined during each phase. BMD in phase 1 was 0.933 g/cm2 and increased to 1.051 and 1.173 g/cm2 after 4 and 7 months of TE, respectively. In phase 3, BMD reached the maximum value (1.275 g/cm2). In phase 4, BMD decreased to 1.180 g/cm2 and was 1.029 g/cm2 at the end of the study protocol. A bilateral necrosis of femoral heads was also detected by x-ray films. In phase 1 serum testosterone was in the normal range, whereas serum estradiol was undetectable. During the 24-month period of treatment with TE (phases 2-4), estradiol was directly related to the amount of TE, whereas LH was inversely related to estradiol serum levels. Estradiol and gonadotropins reached optimal values only in phase 3, when FSH also was near normal; serum testosterone concentrations were normal in phases 3 and 4. This study confirms the role of estrogens in achieving and maintaining bone mineral content in the human male, providing further clinical tools useful in the management of bone loss in aromatase deficiency in the male. We suggest that the adequate substitutive dose of TE for maintaining both bone mass and normal estradiol serum levels in adult men with aromatase deficiency may be 25 microg twice weekly (0.47 microg/kg weekly).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“Taken together, these findings suggest that epiphyseal closure does not develop without the action of estrogen even in the male, and that androgen alone is not sufficient to promote normal skeletal mineralization, because severe osteoporosis was reported in all three patients described to date (6, 8, 9).”
BackgroundEstrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045 · cited 1×
“Few data on the progress of skeletal maturation at different sites are available from the literature in health and disease (33), and longitudinal bone growth remains a poorly understood process (34, 35 ).”
BackgroundMorishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416
Effect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151 · cited 9×
“95 mg/kg weekly) for 6 months as recently reported (8); phase 3, TE treatment (Estraderm, patch system) at the dose of 25 mg twice weekly (0.”
BackgroundMethodInfluentialSelf-citationPrevention of spinal osteoporosis in oophorectomised women
Lindsay, R., Hart, D. M., Forrest, C., & Baird, C. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92592-1 · Cited by 706
Cited by
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
10.1016/b978-1-4160-2911-3.50026-1
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/b978-1-4160-2911-3.50026-1 · Cited by 554
Khosla, S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3555 · Cited by 522
Andropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490
Cooke, P. S., Nanjappa, M. K., Ko, C., Prins, G. S., & Hess, R. A. (2017) · Physiological Reviews · doi:10.1152/physrev.00018.2016 · Cited by 466
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Veldhuis, J. D., Roemmich, J. N., Richmond, E. J., Rogol, A. D., Lovejoy, J. C., Sheffield-Moore, M., Mauras, N., & Bowers, C. Y. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0038 · Cited by 452
“In several patients with rare inborn aromatase deficiency, repletion of estradiol stimulated prompt epiphyseal maturation and bone mineralization, whereas testosterone supplementation did not (243, 271).”
BackgroundVermeulen, A., Kaufman, J. M., Goemaere, S., & Van Pottelberg, I. (2002) · The Aging Male · doi:10.1080/tam.5.2.98.102 · Cited by 452
Maffei, L., Murata, Y., Rochira, V., Tubert, G., Aranda, C., Vazquez, M., Clyne, C. D., Davis, S., Simpson, E. R., & Carani, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030313 · Cited by 342
Self-citationEstrogen and the Male Skeleton
Khosla, S., Melton, L. J., & Riggs, B. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8417 · Cited by 308
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021036 · Cited by 283
Bone Structure at the Distal Radius During Adolescent Growth
Kirmani, S., Christen, D., van Lenthe, G. H., Fischer, P. R., Bouxsein, M. L., McCready, L. K., Melton, L. J., Riggs, B. L., Amin, S., Müller, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081255 · Cited by 278
Estrogens Are Essential for Male Pubertal Periosteal Bone Expansion
Bouillon, R., Bex, M., Vanderschueren, D., & Boonen, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0602 · Cited by 200
Zitzmann, M., Brune, M., Kornmann, B., Gromoll, J., Junker, R., & Nieschlag, E. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01391.x · Cited by 107
Lanfranco, F., Zirilli, L., Baldi, M., Pignatti, E., Corneli, G., Ghigo, E., Aimaretti, G., Carani, C., & Rochira, V. (2008) · Bone · doi:10.1016/j.bone.2008.05.011 · Cited by 105
Self-citationSex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis
Lormeau, C., Soudan, B., d'Herbomez, M., Pigny, P., Duquesnoy, B., & Cortet, B. (2004) · Bone · doi:10.1016/j.bone.2004.01.024 · Cited by 82
Estrogens and Bone Health in Men
Khosla, S., Melton, L. J., & Riggs, B. L. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-1044-8 · Cited by 72
The Aromatase Cytochrome P-450 and Its Clinical Impact
Meinhardt, U., & Mullis, P.-E. (2002) · Hormone Research in Paediatrics · doi:10.1159/000058374 · Cited by 68
“At that time, estrogen replacement therapy should be started at the suggested concentration of 25 μg transdermally twice a week at an average dose of 0.47 μg/kg weekly [”
BackgroundInfluential
Metadata
- Authors
- Rochira, V.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-05-01
- Volume
- 85
- Issue
- 5
- Pages
- 1841-1845
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2125705063
- Cited by
- 142
- References
- 5
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.